Document is current
Any future updates will be listed below
-
Authors
Sardar, Puspendu https://orcid.org/0000-0001-8011-2915
Beresford-Jones, Benjamin S.
Xia, Wangmingyu
Shabana, Omar https://orcid.org/0000-0002-1947-8018
Suyama, Satoshi
Ramos, Ruben J. F. https://orcid.org/0000-0002-3350-0437
Soderholm, Amelia T.
Tourlomousis, Panagiotis
Kuo, Paula
Evans, Alexander C. https://orcid.org/0000-0002-6363-2684
Imianowski, Charlotte J. https://orcid.org/0000-0002-7116-7591
Conti, Alberto G. https://orcid.org/0000-0003-0725-337X
Wesolowski, Alexander J.
Baker, Natalie M. https://orcid.org/0009-0001-0586-2828
McCord, Emily A. L.
Okkenhaug, Klaus https://orcid.org/0000-0002-9432-4051
Whiteside, Sarah K.
Roychoudhuri, Rahul https://orcid.org/0000-0002-5392-1853
Bryant, Clare E. https://orcid.org/0000-0002-2924-0038
Cross, Justin R.
Pedicord, Virginia A. https://orcid.org/0000-0001-9625-3122
-
Funding
Funding for this research was provided by:
Wellcome Trust (206245/Z/17/Z, 302351/Z/23/Z)
Rosetrees Trust (A2194)
EC | Horizon 2020 Framework Programme (EP/X024709/1)
- License Information
-
More Information
Article History
Received: 19 October 2023
Accepted: 13 January 2025
First Online: 10 February 2025
Competing interests
: The authors declare the following competing interests: R.R. holds or has held paid consultancies with Lyell Immunopharma, Achilles Therapeutics and Enhanc3D Genomics and is a principal investigator of research projects funded by AstraZeneca and F-star Therapeutics on unrelated topics that do not constitute competing interests. The other authors declare no competing interests.
